Clinical Trials Directory

Trials / Completed

CompletedNCT01484015

Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

Prolonged Infusion Compared to Standard Infusion Cefepime as Empiric Treatment of Febrile Neutropenia: A Pilot Study

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
70 (actual)
Sponsor
Wake Forest University Health Sciences · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This randomized pilot clinical trial studies how well giving prolonged infusion compared to standard infusion of cefepime hydrochloride works in treating patients with febrile neutropenia. Giving cefepime hydrochloride over a longer period of time may be more effective than giving cefepime hydrochloride over the standard time.

Detailed description

OBJECTIVES: I. The objective of this study is to describe outcomes associated with prolonged infusion (3 hours) compared to standard infusion (30 minutes) cefepime (cefepime hydrochloride) among patients being treated empirically for febrile neutropenia. OUTLINE: Patients are randomized 1 of 2 treatment arms. All patients receive cefepime hydrochloride intravenously (IV) over 30 minutes as their first dose. ARM I: Patients receive cefepime hydrochloride intravenously (IV) over 30 minutes. ARM II: Patients receive cefepime hydrochloride IV over 3 hours. Treatment repeats every 8 hours.

Conditions

Interventions

TypeNameDescription
DRUGcefepime hydrochlorideGiven IV

Timeline

Start date
2011-02-01
Primary completion
2012-06-01
Completion
2012-10-01
First posted
2011-12-02
Last updated
2018-07-18

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT01484015. Inclusion in this directory is not an endorsement.